Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable Disease

Next Previous
Trial Profile

A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable Disease

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDX 1140 (Primary) ; CDX 1140 (Primary) ; CDX 301 (Primary) ; Poly ICLC (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Malignant melanoma; Merkel cell carcinoma; Osteosarcoma; Skin cancer; Soft tissue sarcoma; Squamous cell cancer
  • Focus Adverse reactions

Most Recent Events

  • 07 Jan 2026 Planned End Date changed from 9 Jan 2027 to 9 Jan 2028.
  • 07 Jan 2026 Planned primary completion date changed from 9 Jan 2026 to 9 Jan 2027.
  • 07 Jan 2026 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top